ASCP: American Society of Clinical Psychopharmacology
Conference Coverage
A unique care model for comorbid depression, PTSD
Comorbid PTSD and depression is common, but it is often considered too complex to be managed in a primary care setting.
Conference Coverage
ECT may reduce all-cause mortality in major depression
“If meds and other therapeutics are not working, you should start discussing ECT as a second or third line,” said Dr. Nagy Youssef.
Conference Coverage
Novel drug ‘promising’ for concomitant depression, insomnia
Patients with more severe insomnia at baseline had a greater improvement in depressive symptoms.
Conference Coverage
Social activities may offset psychosis risk in poor communities
Study results showed neighborhood poverty was associated with reduced hippocampal volume, even after controlling for several confounders.
Conference Coverage
At-home vagus nerve stimulation promising for postpartum depression
Auricular VNS uses surface skin electrodes to stimulate nerve endings of a branch of the vagus nerve, located on the surface of the outer ear.
Conference Coverage
Once-weekly oral antipsychotic for schizophrenia on the horizon
LYN-005 was well tolerated in the 85% of study participants who received all three doses.
Conference Coverage
Novel text-messaging program boosts ADHD treatment adherence
"Patients are not going to be fully compliant if they do not understand what the implications are if they do not take their pills," said Dr....
Conference Coverage
New long-term data for antipsychotic in pediatric bipolar depression
Up to 2 years of treatment with lurasidone was associated with continued improvement in depressive symptoms, the investigators reported.
Latest News
Irritability strongly linked to suicidal behavior in major depression
The association between irritability and suicidality was two to 11 times stronger than the link to overall depression, the investigators reported...
Conference Coverage
First-in-class antipsychotic linked to lower cardiometabolic risk
"Lumateperone seems to be the safest antipsychotic we have seen so far," said Dr. Christoph Correll.
Conference Coverage
Esketamine nasal spray prevails in two phase 3 trials
An esketamine nasal spray, combined with an oral antidepressant, is associated with a lower risk of relapse in patients with refractory depression...
Conference Coverage
IV ketamine proves superior to active placebo in low, high doses
MIAMI – Researchers close in on a range of ketamine doses that could provide temporary relief for patients with treatment-resistant depression.
Conference Coverage
‘Motivational pharmacotherapy’ engages Latino patients with depression
MIAMI – Delivering pharmacotherapy in a culturally sensitive way can help improve antidepressant adherence.
Conference Coverage
Expert: Engage patients, clinicians as partners in research
MIAMI – A new research paradigm treats every case as an N of 1 that could improve the care of millions.
Conference Coverage
Patients’ profile deemed best criteria for LAIs in bipolar disorder
MIAMI – Bipolar disorder patients with very severe illness, or who are at the more extreme spectrum in terms of risk, might not be receiving...